

August 2, 2013



Boston Therapeutics to Exhibit at 2013 American Association of Diabetes Educators Annual Meeting & Exhibition in Philadelphia

MANCHESTER, NH -- (Marketwired) -- 08/02/13 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex carbohydrate-based drugs to treat diabetes and inflammatory diseases, will exhibit at the 2013 American Association of Diabetes Educators Annual Meeting & Exhibition (AADE13) in Philadelphia from August 7-9.

Kenneth Tassej, Jr., President, and David Platt, Ph.D., CEO, will be in attendance.

The Company will feature the positive results from its Phase II clinical trial evaluating the safety and efficacy of PAZ320, in which 45 percent of patients responded with a 40 percent reduction of post-meal glucose in the blood compared to baseline in a dose-dependent manner. PAZ320 is a complex carbohydrate-based drug candidate designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. There were no serious adverse events in the Phase II trial conducted at Dartmouth Medical Center in NH.

The AADE13 Annual Meeting & Exhibition is the only large-scale professional event focused solely on diabetes education. AADE13 attendees learn how to improve patient outcomes, teach diverse populations, maximize reimbursement, market diabetes education services and broaden the reach of diabetes education into different practice settings. AADE13 provides strong personal and professional benefits, providing state-of-the-art clinical updates, an exhibit hall full of the latest technologies and treatments, research from thought leaders in the field and unparalleled networking opportunities.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including PAZ320, a non-systemic chewable therapeutic compound designed to reduce the elevation of post-prandial glucose (PPG) or post-meal blood sugar, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

Any statements in this news release about future expectations, plans and prospects for the

Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Director of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

Source: Boston Therapeutics